Beverley Carr, a scientist with commercial experience, has been appointed chief business officer at Amphista Therapeutics Ltd which is developing therapies based on targeted protein degradation. She joins from Achilles Therapeutics Plc, a company developing T cell therapies for cancer, where she was also CBO. Prior to this she headed business development for the immunoinflammation therapy area at GlaxoSmithKline Plc.
Dr Carr received a DPhil in chemistry from the University of Oxford and an MBA from the University of Cambridge, UK.
Amphista Therapeutics announced the appointment on 1 November 2021.
Copyright 2021 Evernow Publishing Ltd